πŸ‡ΊπŸ‡Έ FDA
Patent

US 11267893

Anti-IL36R antibodies

granted A61KA61K2039/505A61K45/06

Quick answer

US patent 11267893 (Anti-IL36R antibodies) held by REGENERON PHARMACEUTICALS, INC. expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K2039/505, A61K45/06, A61K9/0019, A61P